Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Regeneus Ltd. ( (AU:CMB) ) has provided an announcement.
Cambium Bio Limited reported a 9% rise in revenue from ordinary activities to $327,000 for the half-year ended 31 December 2025, alongside other income of $584,000, reflecting modest top-line growth as it advances its regenerative medicine programs. The company still recorded a net loss after tax of $1.46 million, though this loss narrowed by 16% year on year, and its net tangible assets per security improved from negative $0.06 to positive $0.01, indicating a stronger balance sheet but no near-term dividends for shareholders.
These results highlight Cambium Bio’s ongoing investment in clinical development of its ophthalmology and tissue repair candidates while gradually improving its financial position. The shift to a positive net tangible asset base may bolster investor confidence and supports its positioning as a clinical-stage player aiming to commercialise novel treatments for dry eye disease and musculoskeletal conditions.
The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited (ASX:CMB) is a Sydney-based clinical-stage regenerative medicine company developing innovative biologics for ophthalmology and tissue repair. Its proprietary human platelet lysate technology underpins a pipeline of novel therapeutics, led by Elate Ocular for dry eye disease and complemented by the Progenza stem cell platform for knee osteoarthritis and other tissue repair indications.
Average Trading Volume: 8,767
Technical Sentiment Signal: Hold
Current Market Cap: A$12.06M
See more insights into CMB stock on TipRanks’ Stock Analysis page.